Peroxisome proliferator-activated receptor-gamma co-activator-1 (PPARGC1 or PGC1) is one of the genes of current research interest among diabetes and obesity researchers because of its recently described role in orchestrated change of oxidative phosphorylation pathway gene expression. 1 In a recently published article in the International Journal of Obesity, Vimaleswaran et al. 2 presented the association of a synonymous Thr394Thr (G to A) polymorphism in PPARGC1 gene with increased total, visceral and subcutaneous body fat in a cohort of 82 randomly selected diabetic and 82 control individuals of Asian Indian (Southern India) ethnicity. In this Letter to the Editor, I would like to draw the attention to the readers about major analytical and interpretational errors in this article. Hardy-Weinberg equilibrium (HWE) test is commonly used for quality control of genotyping and is one of the few ways to identify systematic genotyping errors.
3 Vimaleswaran et al. 2 used w 2 goodness-of-fit test and concluded in their work that each of the three marker loci was in HWE among both cases (type 2 diabetes, T2DM) and controls (normal glucose tolerant, NGT) separately. Surprisingly, reanalysis of the HWE by the same method using the genotype data provided by the author in Table 1 Das (2006) has pointed out some 'serious analytical and interpretational flaws' in our article. 2 We admit that we had incorrectly stated that all the three loci (Thr394Thr, Gly482Ser and A2962G) are in Hardy-Weinberg equilibrium (HWE) among both cases (Type 2 diabetes) and controls (glucosetolerant individuals). We have mistakenly compared the observed value of the statistic with the tabulated value of the w 2 distribution with 2 degrees of freedom, instead of 1 degree of freedom. This resulted in higher P-values and our incorrect inference that genotype frequencies were not significantly different from those expected under HWE. Indeed, as correctly pointed out by Das, all the three loci show statistically significant departures from HWE among cases. Das has also stated that the A2962G polymorphism is not in HWE among controls. His calculated P-value (0.006) is incorrect; the correct value is 0.02. We note that we have performed six independent tests of HWE (two each for the three polymorphisms), a Pvalue of 0.02 after correcting for multiple comparisons does not provide statistically significant evidence of departure from HWE. Thus, departures from HWE are only observed among cases, which as discussed later are not unexpected and do not invalidate the inferences reported in our paper. Das (2006) has suspected that genotyping errors are responsible for the observed statistically significant deviations from HWE. Although, in principle, this may be true, we believe that it is unlikely for our sample. The reasons are: (a) for each locus, we have carried out duplicate genotypings in a randomly selected subset of 20% individuals and did not find discrepancies, (b) for each locus, all variant genotypes (both homozygotes and heterozygotes for the variant allele) were confirmed by mini-resequencing using an automated DNA sequencer (ABI 310 Genetic Analyzer); and (c) if indeed erroneous genotyping was the cause of departure from HWE, then it is unlikely that the errors would be confined to the case samples and not the control samples. Therefore, the probable reason for departure of observed genotype frequencies among cases for the three loci is not genotyping error but natural selection and linkage-disequilibrium. For any locus that is in strong linkage disequilibrium (LD) with a causal locus for the disease under study, departure from HWE is expected among cases who are likely to have reduced fitness.
Finally, we would like to emphasize that the inference drawn from a test for HWE has no impact on a case-control based association test. In other words, departure from HWE is neither a necessary nor a sufficient condition for obtaining a positive association result. Thus, the reported association of the Thr394Thr polymorphism with Type 2 diabetes is not the result of any analytical or interpretational flaw as claimed by Das. More importantly, the focus of our article, as suggested by the title, was not screening polymorphisms for Type 2 diabetes which, as Das has himself pointed out, was reported in our earlier article, 1 but polymorphisms for quantitative body-fat phenotypes correlated with Type 2 diabetes. For quantitative traits, there are no 'cases' or 'controls'. Although the analyses were performed separately for individuals with Type 2 diabetes and non-glucose tolerance, the analysis of variance method used in the analyses is not affected by departure from HWE. In summary, although we agree that our statement on HWE was incorrect, our inferences on association of the Thr394Thr polymorphism and lack of association of Gly482Ser and A2962G polymorphisms with body-fat phenotypes remain valid and are independent of the fact that the Type 2 diabetes individuals are not in HWE in our sample. 
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